Review question/objective
The objective of this review is to systematically search, appraise and synthesize the best available evidence on risk factors for developing Tuberculosis (TB) after highly active antiretroviral treatment initiation among HIV patients More specifically, the objectives are to identify:
1. The socio demographic risk factors for developing Tuberculosis after highly active anti retro viral treatment initiation 2. Clinical risk factors for developing Tuberculosis after highly active anti retroviral treatment initiation Background Tuberculosis (TB) is one of the most frequent causes of death among adults despite being nearly 100% curable and it infected more than 2 billion people, equal to one-third of the world's population, according to 2009 figures. The current global strategy of TB control is to prevent infection by efficient case finding and treatment and to stop the infection from progressing to an active disease.
1
The TB epidemic has worsened because of the association of TB with the HIV epidemic and the emergence of multidrug resistant TB. The probability of death among HIV positive patients from TB is 20-40 times higher than those not infected with HIV. In 2008, 1.8 million people died from TB, including 500,000 people with HIV-equal to 4500 deaths a day. 2 The increasing rate of human immune deficiency virus (HIV) infection in many countries has had an impact on tuberculosis epidemiology. While TB prevalence has remained stable, TB incidence continues to rise, especially in countries most severely affected by the HIV epidemic as well as those facing political turmoil, migration, poverty and unemployment and where intravenous drug abuse is rampant. 3 HIV is an important risk factor that promotes progression to active TB in people with Mycobacterium tuberculosis infection. The lifetime risk of tuberculosis in immune competent person is 5% to 10%, but in HIV positive individuals, there is a 5% to 15% annual risk of developing active TB disease. 3 It is estimated that almost 33% of all people living with HIV are co infected with both TB and HIV (between 12 and 15 million people) and in parts of sub Saharan Africa, up to 70% of TB patients are co infected with HIV. 4 Similarly it is estimated that up to 33% of all AIDS deaths worldwide can be directly attributed to TB and in sub-Saharan Africa this increases to 50%. 4 Tuberculosis and HIV together are responsible for the deaths of over 4 million people annually. 5 TB is one of the most common infectious diseases that threaten people living with HIV in the developing world and of the 1.7 million deaths from TB in 2008, almost one third were people co infected with HIV or AIDS. 5 There appears to be little research addressing HIV and TB co infection. The WHO reports that only 2.4% of all people living with HIV or AIDS are even being tested for TB and this low rate of screening is shocking, given that TB causes a third of global HIV/AIDS deaths. 6 It is possible that, in addition to increasing individual susceptibility to TB following Mycobacterium tuberculosis (MTB) infection, the increased burden of HIV-associated TB cases also increases MTB transmission rates at the community level, threatening the health and survival of HIV-negative individuals as well. 7 In several countries HIV has been associated with epidemic outbreaks of TB, and many of the reported outbreaks involved multidrug-resistant strains responding poorly to standard therapy. [8] [9] [10] [11] [12] 13 Available research 14, 15 16 To date there are no systematic reviews which have examined the risk factors for developing TB among HIV patients who are on HAART. Therefore, this review will provide the best available evidence for the specified topic so that it can be utilised in the evidence based decision making for treating patients.
For this systematic review the following definitions will be used.
HAART: is an approach when several anti retro viral (ARV) drugs, typically three or four are taken in combination. 
Initiation of HAART

Inclusion criteria
Types of participants
This review will consider studies that include HIV patients who have initiated highly active anti retro viral treatment (HAART) who is above 15 years of age.
Focus of the review
This review will consider studies that evaluate risk factors for developing active tuberculosis among HIV patients after initiation of highly active anti retro viral treatment (HAART). 
Types of outcomes
Types of studies
This review will consider analytical epidemiological study designs including prospective and retrospective cohort studies and case control studies.
Search strategy
The search strategy aims to find both published and unpublished studies. A three-step search strategy will be utilised in this review.
1. An initial limited search of MEDLINE and CINAHL will be undertaken followed by analysis of the text words contained in the title and abstract, and of the index terms used to describe article.
2.
A second search using all identified keywords and index terms will then be undertaken across all included databases.
3. Thirdly, the reference list of all identified reports and articles for consideration of analysis will be searched for additional studies.
Electronic searches will be made through PubMed, CINAHL, EMBASE, The Cochrane and JBI Library of Systematic Reviews, Government websites, and specific journals accessed through HINARI, Pop line, and MedNar searches will also be conducted. We will also search the World Bank's JOLIS search engine, British Library for Development Studies at IDS as well as IDEAS databases of unpublished working papers. Studies published in English will be considered for inclusion in this review from January 1997, which is the time since when HAART has been introduced to December
2011.
All studies identified during the database search will be assessed for relevance to the review and full reports will be retrieved for the studies meeting the inclusion criteria after being assessed by the two reviewers independently.
The initial search terms to be used are as specified below and will be modified according to the various databases and search engines: 
Assessment of methodological quality
Papers selected for retrieval will be assessed by two independent reviewers for methodological validity prior to inclusion in the review using standardised critical appraisal instruments from the Joanna Briggs Institute Meta Analysis of Statistics Assessment and Review Instrument (JBI-MAStARI) (Appendix I). Any disagreements that arise between the reviewers will be resolved through discussion, or with a third reviewer.
Data collection
Data will be extracted from papers included in the review using the standardized data extraction tool from JBI-MAStARI (Appendix II). The data extracted will include specific details about the interventions, populations, study methods and outcomes of significance to the review question and specific objectives.
Data synthesis
Quantitative data will, where possible, be pooled in statistical meta-analysis using JBI-MAStARI. All results will be subject to double data entry. Effect sizes expressed as relative risk or hazard ratio for cohort studies and odds ratio for case control studies and their 95% confidence intervals will be calculated for analysis. A Random effects model will be used and heterogeneity will be assessed statistically using the standard Chi-square test. Where statistical pooling is not possible the findings will be presented in narrative form including tables and figures to aid in data presentation where appropriate.
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